Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device : a prospective open-label Scandinavian noninterventional study (the ScanSmart study). / Pedersen, Elena Didenko; Stenager, Egon; Vadgaard, J L; Jensen, M B; Schmid, R; Meland, N; Magnussen, G; Frederiksen, Jette L.

I: Patient Preference and Adherence, Bind 12, 2018, s. 569-575.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Pedersen, ED, Stenager, E, Vadgaard, JL, Jensen, MB, Schmid, R, Meland, N, Magnussen, G & Frederiksen, JL 2018, 'Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)', Patient Preference and Adherence, bind 12, s. 569-575. https://doi.org/10.2147/PPA.S154417

APA

Pedersen, E. D., Stenager, E., Vadgaard, J. L., Jensen, M. B., Schmid, R., Meland, N., ... Frederiksen, J. L. (2018). Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). Patient Preference and Adherence, 12, 569-575. https://doi.org/10.2147/PPA.S154417

Vancouver

Pedersen ED, Stenager E, Vadgaard JL, Jensen MB, Schmid R, Meland N o.a. Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). Patient Preference and Adherence. 2018;12:569-575. https://doi.org/10.2147/PPA.S154417

Author

Pedersen, Elena Didenko ; Stenager, Egon ; Vadgaard, J L ; Jensen, M B ; Schmid, R ; Meland, N ; Magnussen, G ; Frederiksen, Jette L. / Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device : a prospective open-label Scandinavian noninterventional study (the ScanSmart study). I: Patient Preference and Adherence. 2018 ; Bind 12. s. 569-575.

Bibtex

@article{c196b9e4a60d4b6c9612461999a7c2f6,
title = "Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)",
abstract = "Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart{\circledR} and assess injection-site reactions and treatment satisfaction.Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13-23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83{\%} female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89{\%} (n=48) of patients had ≥90{\%} adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78{\%}) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.",
author = "Pedersen, {Elena Didenko} and Egon Stenager and Vadgaard, {J L} and Jensen, {M B} and R Schmid and N Meland and G Magnussen and Frederiksen, {Jette L}",
year = "2018",
doi = "10.2147/PPA.S154417",
language = "English",
volume = "12",
pages = "569--575",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device

T2 - a prospective open-label Scandinavian noninterventional study (the ScanSmart study)

AU - Pedersen, Elena Didenko

AU - Stenager, Egon

AU - Vadgaard, J L

AU - Jensen, M B

AU - Schmid, R

AU - Meland, N

AU - Magnussen, G

AU - Frederiksen, Jette L

PY - 2018

Y1 - 2018

N2 - Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction.Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13-23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.

AB - Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction.Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13-23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.

U2 - 10.2147/PPA.S154417

DO - 10.2147/PPA.S154417

M3 - Journal article

C2 - 29720872

VL - 12

SP - 569

EP - 575

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -

ID: 213034853